Abivax (STU:2X1) Institutional Ownership : 5.91% (As of Mar. 15, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Abivax Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Abivax's institutional ownership is 5.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Abivax's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Abivax's Float Percentage Of Total Shares Outstanding is 82.27%.

Abivax Institutional Ownership Historical Data

The historical data trend for Abivax's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Institutional Ownership Chart

Abivax Historical Data

The historical data trend for Abivax can be seen below:

	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31
Institutional Ownership	5.81	5.81	5.88	5.96	6.01	6.02	6.00	5.96	6.00	5.91

Abivax Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Abivax Headlines

No Headlines